PNC-27
Evidence: CExperimental / Early Research
Evidence Snapshot
Regulatory Context
PNC-27 is an experimental research peptide, not an approved cancer therapy. No FDA-approved indication was identified for the exact compound in this research pass.
Research Takeaway
PNC-27 has been studied as a p53-derived chimeric peptide that binds membrane-associated HDM-2/MDM2 on susceptible cancer cells and can promote transmembrane pore formation followed by cell lysis/necrosis.
See all 6 evidence claims →Quick Summary
PNC-27 is a chimeric 32-residue experimental anticancer peptide studied for its ability to bind membrane-associated HDM-2/MDM2 on cancer cells and trigger targeted cell lysis. Evidence is limited to in-vitro, ex-vivo, and animal cancer models; no human clinical efficacy has been established.
Mechanism & Research Overview
PNC-27 has been studied as a p53-derived chimeric peptide that binds membrane-associated HDM-2/MDM2 on susceptible cancer cells and can promote transmembrane pore formation followed by cell lysis/necrosis.
Evidence Claims
Individual scientific statements drawn from the sources cited below, each shown with the specific evidence boundary that statement does not establish.
Supported
PNC-27 has been studied as a p53-derived chimeric peptide that binds membrane-associated HDM-2/MDM2 on susceptible cancer cells and can promote transmembrane pore formation followed by cell lysis/necrosis.
Sources: Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and targets HDM-2 in cancer-cell membranes; Structural/mechanistic study of PNC-27-HDM-2 complexes; Mechanistic study of PNC-27 blockade at the p53-binding region of HDM-2 and mitochondrial membrane effects
Supported
In-vitro, ex-vivo, and animal studies report cytotoxic activity across several cancer models, including pancreatic, breast, ovarian, leukemia, and cervical models.
Sources: PNC-27 induces tumor-cell lysis as an intact peptide; PNC-27 kills K562 leukemia cells dependent on membrane HDM-2; Ex-vivo PNC-27 activity against primary ovarian cancer cells and chemotherapy-resistant ovarian cancer lines; PNC-27 activity against cervical cancer cell lines
Supported
Experimental studies report lower toxicity toward selected non-transformed comparator cells, but this laboratory selectivity does not establish clinical safety in humans.
Supported
An ovarian cancer model reported synergy between PNC-27 and paclitaxel; this is preclinical combination evidence, not a validated clinical regimen.
Sources: PNC-27 and paclitaxel synergy in ovarian cancer models
Supported
No adequate human therapeutic trial evidence was identified to establish efficacy, dosing, safety, or survival benefit for PNC-27.
Supported
PNC-27 should be presented as an experimental research peptide, not an approved cancer therapy. No FDA-approved indication was identified for the exact compound in this research pass.
Sources: MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check
Safety & Evidence Limitations
Considerations reported in the sources cited on this page — not a complete list of every possible risk, and not medical advice.
Higher-Priority Safety Consideration
Do not phrase as "treats cancer," "cures cancer," or "safe alternative to chemotherapy." All evidence is preclinical.Safety Consideration
No adequate human therapeutic trial evidence was identified to establish efficacy, dosing, safety, or survival benefit.Safety Consideration
Repeated direct laboratory evidence supports cancer-cell cytotoxicity, but the research base remains concentrated among closely connected investigators, limiting independent replication.
Research Areas Being Studied
Research areas discussed on this page reflect the Experimental / Early Research category and the sources cited below.
Findings Reported in Studies
Educational summary only — reported in cited studies, not a claim of proven benefit.
No Human Study Findings Listed Yet
See preclinical, regulatory, and review sources below.
Study Tables by Evidence Type
Human Studies & Clinical Data
No Human Studies & Clinical Data Listed Yet
This section will be updated as sources are added.
Animal / Cell / Preclinical Data
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| PNC-27 activity against cervical cancer cell lines | 2025 | PNC-27 showed cytotoxic activity against cervical cancer cell lines, extending the range of cancer models with reported activity. | |||
| Mechanistic study of PNC-27 blockade at the p53-binding region of HDM-2 and mitochondrial membrane effects | 2024 | Mechanistic work showing PNC-27 blockade at the p53-binding region of HDM-2, with reported effects on mitochondrial membranes. | |||
| Structural/mechanistic study of PNC-27-HDM-2 complexes | 2022 | Structural/mechanistic analysis of PNC-27-HDM-2 complexes, further characterizing the proposed membrane-binding mechanism. | |||
| PNC-27 and paclitaxel synergy in ovarian cancer models | 2017 | Combining PNC-27 with paclitaxel produced synergistic cytotoxic effects in ovarian cancer models; this is preclinical combination evidence, not a validated clinical regimen. | |||
| Ex-vivo PNC-27 activity against primary ovarian cancer cells and chemotherapy-resistant ovarian cancer lines | 2015 | PNC-27 showed cytotoxic activity against primary ex-vivo ovarian cancer cells, including chemotherapy-resistant lines. | |||
| PNC-27 kills K562 leukemia cells dependent on membrane HDM-2 | 2014 | PNC-27 cytotoxicity against K562 leukemia cells depends on membrane-expressed HDM-2, supporting the membrane-HDM-2 targeting mechanism in a hematologic cancer model. | |||
| Anticancer peptide PNC-27 adopts an HDM-2-binding conformation and targets HDM-2 in cancer-cell membranes | 2010 | PNC-27 adopts a conformation that binds membrane-associated HDM-2/MDM2 on cancer-cell membranes, supporting the core proposed mechanism of targeted membrane lysis. | |||
| PNC-27 induces tumor-cell lysis as an intact peptide | 2010 | The intact PNC-27 peptide (not a metabolite or fragment) is responsible for tumor-cell lysis in vitro. |
Regulatory Documents & Official Trial Registries
| Title | Year | Population / Model | Dose / Duration / Finding | Safety Notes | Source |
|---|---|---|---|---|---|
| MitoCore Batch 9 regulatory search: FDA approval status and ClinicalTrials.gov registration check | 2026 | Direct search performed 2026-08-17 for FDA drug-approval status and ClinicalTrials.gov interventional-trial registration for PNC-27, Pancragen, Bronchogen, Testagen, Chonluten, Prostamax, Ovagen, and N-Acetyl Epitalon Amidate (Ac-AEDG-NH2), including known aliases and sequence names. No FDA-approved drug product was identified for any of the eight compounds. No registered ClinicalTrials.gov interventional trial was identified for any of the eight compounds. All eight are marketed exclusively through peptide/research-chemical vendors as research-use-only products, not as approved medicines. Absence from these searches is not itself a formal FDA determination and does not establish safety or ineffectiveness -- it establishes only that no approval or registered trial was located in this search pass. |
Anecdotal Reported Patterns — Not Medical Advice
Anecdotal Reported Patterns — Not Medical Advice
Reported dosing patterns are included for educational context only. They are self-reported, unverified, not medical advice, and not instructions for human use. Community-submitted patterns are not yet available in this Phase 1 prototype; this section is a placeholder reserved for moderated, aggregated community data.
Lab Markers to Discuss With a Clinician
Educational topics only — not self-monitoring instructions.
FAQ
Disclaimer
Educational information only. This page summarizes published preclinical research and does not provide medical advice, a recommendation, or instructions for human use.
Educational use only. This content is provided for informational and research-summary purposes only. It is not medical advice, not a treatment recommendation, not a dosing guide, and not a substitute for care from a licensed medical professional. Nothing here is intended to diagnose, treat, cure, prevent, or mitigate disease. Reported dosing patterns, when shown elsewhere on the site, must be labeled either as Study / Trial Dosing or Anecdotal Reported Patterns — Not Medical Advice. Community reports are self-reported, unverified, and not scientific proof.
Community-reported experiences, once enabled, must be displayed only as moderated, anonymized, or aggregated data. They are anecdotal, self-reported, unverified, and should never be presented as proof of safety, efficacy, or expected results.
Content status: Content pending review. Last updated 2026-08-17.
Follow research updates for PNC-27
Get notified in your MitoCore account when this profile is updated, a new study is added, or its evidence grade changes.
Get updates when new studies or safety notes are added for this peptide.
Get educational updates on new studies, evidence-grade changes, and safety notes. Educational content only — not medical advice.